secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2022-02-28T23:59:59+00:00
Accession:  0000950170-22-002162
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam reports $1.2B cash post-Pfizer deal; H2 2022 IND milestones set for SCD programs
--------------------------------------------------------------------------------

- Pfizer collaboration: $300M upfront, up to $1.35B milestones for in vivo base editing programs.
- Cash $1.2B including Pfizer payment; Q4 net loss $64.7M ($0.95/shr), FY net loss $370.6M ($5.77/shr).
- Planned H2 2022 IND submissions: BEAM-101 (SCD Phase 1/2), BEAM-102 (SCD), BEAM-201 (T-ALL/TLL).
- IND-enabling studies for BEAM-301 (liver-targeted GSDIa) in 2022; second CAR-T candidate nomination due.
- R&D expenses $96.8M Q4 (up from $32.5M), G&A $17.8M Q4 (up from $8.4M) YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000095017022002162/0000950170-22-002162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000095017022002162/beam-20220228.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-002162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer